Publication: 269

Publication: 269

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

PubMed

DOI

Google Scholar

Citation:: J Clin Oncol vol 26 (14) 2364-72

Year:: 2008
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:
Grants:: CA33601, P30 CA016672, CA77406, UO1CA64507, CA77651, CA60138, CA35279, UO1CA64061, CA47559, CA31946, R01CA45708

Corr. Author:
Authors:: Michael P DiGiovanna David F Stern Susan Edgerton Gloria Broadwater Lynn G Dressler Daniel R Budman I Craig Henderson Larry Norton Edison T Liu Hyman B Muss Donald A Berry Daniel F Hayes Ann D Thor

Networks:

Study: Alliance-8541
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:

Keywords:: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Disease-Free Survival, Dose-Response Relationship, Drug, Doxorubicin, Enzyme Activation, Female, Fluorouracil, Gene Dosage, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Lymphatic Metastasis, Neoplasm Staging, Phosphorylation, Receptor, ErbB-2